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INTRODUCTION
Sclerosing cholangitis includes a spectrum of chronic, 
variably progressive cholestatic liver disease characterized 
by inflammation, fibrosis, and stricture of the intrahepatic 
Sclerosing Cholangitis: Clinicopathologic Features, 
Imaging Spectrum, and Systemic Approach to 
Differential Diagnosis
Nieun Seo, MD1, So Yeon Kim, MD, PhD2, Seung Soo Lee, MD, PhD2, Jae Ho Byun, MD, PhD2,  
Jin Hee Kim, MD, PhD2, Hyoung Jung Kim, MD, PhD2, Moon-Gyu Lee, MD, PhD2
1Department of Radiology, Research Institute of Radiological Science, Severance Hospital, Yonsei University College of Medicine, Seoul 03722, 
Korea; 2Department of Radiology and Research Institute of Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, 
Korea
Sclerosing cholangitis is a spectrum of chronic progressive cholestatic liver disease characterized by inflammation, fibrosis, 
and stricture of the bile ducts, which can be classified as primary and secondary sclerosing cholangitis. Primary sclerosing 
cholangitis is a chronic progressive liver disease of unknown cause. On the other hand, secondary sclerosing cholangitis has 
identifiable causes that include immunoglobulin G4-related sclerosing disease, recurrent pyogenic cholangitis, ischemic 
cholangitis, acquired immunodeficiency syndrome-related cholangitis, and eosinophilic cholangitis. In this review, we suggest 
a systemic approach to the differential diagnosis of sclerosing cholangitis based on the clinical and laboratory findings, as 
well as the typical imaging features on computed tomography and magnetic resonance (MR) imaging with MR 
cholangiography. Familiarity with various etiologies of sclerosing cholangitis and awareness of their typical clinical and 
imaging findings are essential for an accurate diagnosis and appropriate management.
Index terms: Bile ducts; Sclerosing cholangitis; CT; MRI; Differential diagnosis
Received August 19, 2015; accepted after revision October 23, 
2015.
This study was supported by Grant #2012R1A1A1012731 by 
Basic Science Research Program through the National Research 
Foundation of Korea (NRF) funded by the Ministry of Education, 
Science and Technology, Korea.
Corresponding author: So Yeon Kim, MD, PhD, Department of 
Radiology and Research Institute of Radiology, Asan Medical 
Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-
gil, Songpa-gu, Seoul 05505, Korea.
• Tel: (822) 3010-5980 • Fax: (822) 476-4719
• E-mail: sykimrad@amc.seoul.kr
This is an Open Access article distributed under the terms of 
the Creative Commons Attribution Non-Commercial License 
(http://creativecommons.org/licenses/by-nc/3.0) which permits 
unrestricted non-commercial use, distribution, and reproduction in 
any medium, provided the original work is properly cited. 
Korean J Radiol 2016;17(1):25-38
and extrahepatic bile ducts (1). Sclerosing cholangitis can 
be divided into primary sclerosing cholangitis (PSC) of 
unidentified etiology and secondary sclerosing cholangitis 
caused by various identifiable etiologies, including 
immunoglobulin G4-related sclerosing cholangitis (IgG4-
SC), recurrent pyogenic cholangitis (RPC), ischemic 
cholangitis, acquired immunodeficiency syndrome (AIDS)-
related cholangitis, and eosinophilic cholangitis. The 
diagnosis of PSC requires the exclusion of secondary 
causes of sclerosing cholangitis. Furthermore, contrary to 
PSC in which liver transplantation is recommended as a 
curative treatment option, secondary sclerosing cholangitis 
can respond favorably to treatment for related causes. 
Therefore, awareness of the imaging features of primary and 
secondary sclerosing cholangitis and the clinical setting are 
important for accurate diagnosis in patients with sclerosing 
cholangitis.
In this article, we describe the imaging findings of 
the various spectrums of sclerosing cholangitis with an 
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emphasis on a systemic approach in differential diagnosis. 
We also discuss the clinical significance of and therapeutic 
options for treating sclerosing cholangitis.
Primary Sclerosing Cholangitis
Primary sclerosing cholangitis is a chronic, progressive 
liver disease with inflammation and fibrosis of the bile 
ducts of unidentified etiology, which finally progresses to 
biliary cirrhosis and portal hypertension (2, 3). 
The prevalence of PSC is approximately 10/100000 in 
Northern Europe (4, 5) and the USA, while it is far less 
common in Southern Europe and Asia (6, 7). PSC affects 
men twice as often as women, and generally young 
patients with an age of onset of 30–40 years. PSC has 
a strong association with inflammatory bowel diseases. 
Approximately 60 to 80% of patients with PSC present with 
inflammatory bowel disease of which, 87% have ulcerative 
colitis and 13% have Crohn’s disease (8, 9). The clinical 
presentation can vary, including cholestatic laboratory 
findings and nonspecific symptoms including right upper 
quadrant pain or jaundice.
Although the pathogenesis remains to be elucidated, 
many experts accept an autoimmune component (10-12). 
A typical histopathologic feature of PSC is substantial 
periductal (“onion-skin”) fibrosis with minimal inflammatory 
cells (Fig. 1). However, this finding is observed in 
< 20% of cases and may also be found in secondary 
sclerosing cholangitis (13). Therefore, a liver biopsy is not 
recommended for the diagnosis of PSC in patients with 
typical cholangiographic findings (14).
Diagnosis of PSC can be made by typical cholangiographic 
findings and the exclusion of secondary causes. Both the 
American Association for the Study of Liver Diseases and the 
European Association of the Study of the Liver guidelines 
recommend magnetic resonance (MR) cholangiography as 
the first option for cholangiography in cases of suspected 
PSC, and endoscopic cholangiography for non-diagnostic 
cases (14, 15). The typical MR cholangiographic features 
include diffuse, multifocal short segmental strictures and 
mild dilatation in the intrahepatic and extrahepatic bile 
Fig. 1. Pathology of primary sclerosing cholangitis.
Photomicrograph of liver biopsy specimen (original magnification, 
x 400; hematoxylin and eosin stain) reveals fibrous portal widening 
with concentric onion-skin fibrosis around interlobular bile duct and 
moderate degree of mixed inflammatory cell infiltration (arrows).
Fig. 2. Primary sclerosing cholangitis in 36-year-old male.
A. Contrast-enhanced axial CT image demonstrates mild multifocal wall thickening in intrahepatic and extrahepatic bile ducts (arrows). B. MR 
cholangiography shows multiple and short segmental strictures in intra- and extrahepatic bile ducts (arrows), as well as diverticular outpouching 
(arrowheads).
A B
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ducts alternating with normal ducts, which sometimes 
produce “beaded” appearance (Figs. 2, 3). As the fibrosis 
progresses and strictures worsen, the peripheral bile 
ducts are obliterated and become poorly visualized on MR 
cholangiography showing a “pruned tree” appearance (Fig. 
3) (16). Diverticular outpouching of bile ducts is another 
characteristic finding that occurs in up to 27% of the 
patients with PSC (Fig. 2) (17). Almost half of patients with 
PSC have some degree of mural irregularity causing a shaggy 
or nodular appearance of the bile ducts (18). PSC commonly 
involves both intrahepatic and extrahepatic ducts in 75% 
of patients, whereas involvement of only the extrahepatic 
bile duct is uncommon (10% of patients) and isolated 
involvement of the intrahepatic bile ducts is reported in 
15% of patients (3). Bile duct stones are detected in 8% of 
these patients (16). 
Abdominal ultrasonography (US) is generally non-
diagnostic, although thickened or focal dilated bile ducts 
are observed in PSC patients. Computed tomography (CT) 
demonstrates alternating narrowing and dilatation of the 
bile ducts with contrast enhancement in PSC (19). CT and 
MR imaging also show associated parenchymal changes of 
the liver, as well as ductal changes in PSC. A rounded liver 
appearance is observed due to hypertrophy of the caudate 
lobe and atrophy of the left lateral and right posterior 
segments in PSC (9). In PSC, T2-weighted MR images show 
Fig. 3. Chronologic change of PSC in 36-year-old male.
A. MR cholangiography image depicts multifocal alternating strictures and dilatation of intrahepatic bile ducts (arrows). B. Follow-up endoscopic 
cholangiography obtained 5 years after MR cholangiography (A) shows obliterated peripheral bile ducts, resulting in “pruned tree” appearance 
(arrows). Extrahepatic bile duct is dilated (arrowhead). MR = magnetic resonance, PSC = primary sclerosing cholangitis
A B
Fig. 4. Pathology of IgG4-related SC.
A. Photomicrograph of liver biopsy specimen (original magnification, x 400; hematoxylin and eosin stain) shows fibrous portal widening with 
concentric fibrosis and moderate degree of mixed inflammatory cells infiltration (arrows) around interlobular bile duct (arrowhead) (curved arrow, 
arteriole; asterisk, portal venule). B. There are abundant IgG4-positive plasma cells around bile ducts (arrowheads) (original magnification, x 
400; IgG4 staining). IgG4 = immunoglobulin G4, SC = sclerosing cholangitis
A B
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a wedge-shaped or reticular heterogeneous area of high-
signal intensity with peripheral distribution (20). 
Patients with PSC have a 10 to 15% risk of developing 
cholangiocarcinomas, and a 7 to 9% chance of a 10-year 
cumulative incidence of cholangiocarcinomas (16, 21). 
Diagnostic evaluation of suspected cholangiocarcinoma 
includes serum cancer antigen 19-9, imaging studies such 
as MR, CT and endoscopic cholangiography with brushing or 
cytology (14). Of the imaging findings, malignant appearing 
mass compatible with cholangiocarcinoma is the most 
direct finding, although masses are uncommon in the early 
stage of cholangiocarcinoma. Progressive ductal dilatation 
seen in follow-up studies, marked ductal dilatation, 
severe ductal narrowing, mural thickening, and intraductal 
polypoid lesions in PSC are also highly suggestive of 
cholangiocarcinoma (9, 16).
Medical therapy such as the use of ursodeoxycholic acid, 
corticosteroids or other immunosuppressive agents have 
Fig. 5. IgG4-related SC in 77-year-old male.
A. Contrast–enhanced axial CT image shows mildly enhanced wall thickening of common hepatic duct (arrow) with mild dilatation of intrahepatic 
bile ducts (arrowheads). B. MR cholangiography shows focal stricture of intrapancreatic bile duct (arrow), as well as multifocal stricture in right 
intrahepatic bile ducts (arrowheads). IgG4 = immunoglobulin G4, MR = magnetic resonance, SC = sclerosing cholangitis
A B
Table 1. Comparison of Primary Sclerosing Cholangitis, IgG4-Related Sclerosing Cholangitis, and Recurrent Pyogenic Cholangitis
Variables Primary Sclerosing Cholangitis IgG4-Related Sclerosing Cholangitis Recurrent Pyogenic Cholangitis
Geographic distribution Northern Europe and USA Worldwide East Asia
Age 4–5th decades 7th decades (mean age: 63 years) 6–7th decades
Gender M:F = 2–3:1 M:F = 8:1 Equal sex incidence
Clinical symptom Variable Obstructive jaundice Epigastric pain, fever, jaundice
Serum IgG4 level Not elevated Elevated Not elevated
Associated disease Inflammatory bowel disease
Autoimmune pancreatitis or other 
  IgG4-related disease
Parasitic infestation including 
  Clonorchiasis
Microscopic findings
Periductal fibrosis (“onion skin-
  type”) around medium-sized to 
  large bile ducts
Lymphoplasmacytic infiltration 
  with abundant IgG4-positive 
  plasma cells and storiform 
  fibrosis
Bilirubinate stones and fibrous 
  thickening of ectatic large ducts
Radiologic findings
Typically “beaded” appearance 
  involving both intra- and 
  extrahepatic bile ducts
Diverticular outpouching
Pruned-tree appearance at 
  chronic stage
Prominent bile duct wall 
  thickening with visible lumen
Stricture in intrapancreatic 
  bile ducts 
Findings of autoimmune 
  pancreatitis or other IgG4-
  related systemic disease
Bile duct calculi 
Dilatation of central bile 
  ducts
Abrupt non-visualization 
  of peripheral bile duct
Response to steroid None Good None
IgG4 = immunoglobulin G4
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shown only limited success in patients with PSC (22). In 
patients with advanced liver disease, liver transplantation 
is recommended as a curative treatment option (14). 
Recurrence of PSC after liver transplantation occurs in 20 to 
25% of patients 5 to 10 years after the liver transplantation 
(23).
Secondary Sclerosing Cholangitis
IgG4-Related Sclerosing Cholangitis 
Immunoglobulin G4-SC is bile duct involvement of IgG4-
related systemic disease (IgG4-RD) (24). After the pancreas, 
bile ducts are the second most common organ, involved 
with IgG4-RD. Patients with IgG4-SC are predominantly 
males in their 60s (mean age, 63 years) (25). Patients with 
IgG4-SC commonly present with obstructive jaundice. Like 
other IgG4-related diseases, the serum IgG4 is frequently 
elevated. 
Immunoglobulin G4-SC shares the immunohistopathologic 
features of other IgG4-RD, including autoimmune 
pancreatitis, which is characterized by lymphoplasmacytic 
infiltration with abundant IgG4-positive plasma cells, 
storiform interstitial fibrosis, and obliterative phlebitis (Fig. 
4) (26). 
Abdominal US has limited value for diagnosing IgG4-
SC, although it may show thickening of the bile duct and 
gallbladder. In cases of IgG4-SC, cross-sectional imaging, 
such as CT or MR imaging, demonstrates long-segmental, 
symmetrical, circumferential wall thickening and delayed 
contrast enhancement of the involved bile ducts (Fig. 5) 
(27). In approximately half of these patients, the involved 
bile duct lumens are narrowed, although visible (28). The 
most commonly involved location is the intrapancreatic 
segment of the common bile duct (CBD) followed by 
the hilar bile ducts in IgG4-SC (Fig. 5) (29). Multifocal 
involvement of both intrahepatic and extrahepatic bile 
ducts can occur, similar to PSC, while isolated stricture 
of the distal CBD can also be observed in IgG4-SC. The 
cholangiographic findings of IgG4-SC include long and 
continuous stricture of the bile ducts with prestenotic 
dilatation (Fig. 5) (30). Lymphadenopathy is not uncommon 
in patients with IgG4-SC (24). In particular, extrabiliary 
findings associated with IgG4-RD involvement, including 
the pancreas, kidney or retroperitoneal fibrosis, strongly 
suggest IgG4-SC (27). 
Differentiation of IgG4-SC from other types of 
sclerosing cholangitis, especially from PSC, is clinically 
important as IgG4-SC shows a dramatic response to 
steroid therapy (Table 1) (31). Patients with PSC are 
generally younger and less symptomatic than those 
with IgG4-related disease. Multifocal intrahepatic duct 
involvement with short segmental strictures as well as a 
beaded, pruned-tree, and diverticulum-like appearance 
are imaging features suggestive of PSC. As IgG4-SC 
sometimes presents with prominent wall thickening in 
the bile duct, cholangiocarcinoma can be included as a 
differential diagnosis. Imaging features more suggestive of 
cholangiocarcinoma than of IgG4-SC include solitary lesion 
with irregular margins, eccentric wall thickening, invisible 
bile duct lumen in the involved segment, more prominent 
wall thickening (> 3 mm) and contrast enhancement, and 
an abrupt transition between the normal and involved bile 
duct (32). In patients with an inconclusive diagnosis, a 
steroid trial could be considered for the diagnosis of IgG4-
SC in selected patients (33).
Recurrent Pyogenic Cholangitis
Recurrent pyogenic cholangitis is a progressive biliary 
disease characterized by recurrent episodes of cholangitis 
and intrahepatic pigmented stones (34). RPC is prevalent 
in Asian countries (35) and equally affects patients of 
both sexes (36, 37). Patients with RPC are commonly in 
the sixth and seventh decades of life and of rural and low 
socioeconomic status (36, 37). These patients typically 
present with abdominal pain, fever, and jaundice (the 
Charcot triad) and often have a history of recurrent 
episodes. The laboratory tests in RPC may demonstrate 
leukocytosis and elevated serum bilirubin. 
Although the exact pathogenesis of RPC is unknown, 
strong associations with parasitic infestation such 
as Clonorchis sinensis or Ascaris lumbriocoides, portal 
bacteremia, and malnutrition are suggested (36, 38). 
Chronic recurrent infection of the bile ducts is thought to 
induce biliary stricture, bile stasis, and pigmented biliary 
stones. Approximately 30 to 80% of the stones in RPC 
are calcium bilirubinate stones commonly found in the 
intrahepatic bile duct (39). Histologically, bile ducts and 
periductal tissue show fibrous mural thickening, as well 
as acute and chronic inflammatory changes in RPC (38). 
The hepatic segments containing stones demonstrate 
parenchymal atrophy and scarring (38). 
The diagnosis of RPC is based on the demographic 
background, as well as the clinical and imaging features. 
Abdominal US in RPC shows bile duct dilatation with 
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increased periportal echogenicity. The intrahepatic bile 
duct stones can show various degrees of echogenicity 
and posterior shadowing (40). CT in RPC demonstrates 
disproportional dilatation of central intrahepatic ducts 
and extrahepatic bile ducts with nondilated or minimally 
dilated peripheral ducts, leading to decreased arborization 
and abrupt tapering of bile ducts (Fig. 6). Up to 90% of 
hepatolithiasis show hyperattenuation on unenhanced CT 
images, as compared to normal liver parenchyma (Fig. 6) 
(36, 41). Parenchymal atrophy occurs most frequently in 
the left lateral segment and the right posterior segment, 
while hypertrophy occurs in the caudate lobe and left 
medial segment, thus producing a round liver appearance 
in RPC. Heterogeneous parenchymal enhancement and 
periductal enhancement are often seen during acute 
exacerbations (42). For evaluation of patients with 
RPC, MR cholangiography is preferred to endoscopic 
cholangiography, since it can evaluate the bile ducts 
proximal to an obstruction and has no risk for biliary sepsis 
(40). However, endoscopic cholangiography has advantages 
for allowing therapeutic intervention. Cholangiography in 
RPC demonstrates dilatation of the central bile ducts and 
rapid tapering in the peripheral bile ducts, known as the 
arrowhead appearance (Fig. 6) (43). Strictures usually occur 
in the intrahepatic bile ducts (43). MR is more sensitive 
than CT for detecting radiolucent stones, which can appear 
hypointense on T2-weighted images and isointense to 
hyperintense on T1-weighted images (44). On the other 
hand, pneumobilia, which is commonly seen in RPC, can 
often mimic intrahepatic stones on MR or US, while it 
Fig. 7. Recurrent pyogenic cholangitis with Clonorchis sinensis infestation in 62-year-old male.
A. Contrast-enhanced CT image shows diffuse dilatation of intrahepatic bile ducts, especially in peripheral portion of bile ducts (arrows). B. MR 
cholangiography shows marked peripheral intrahepatic bile duct dilatation without central bile duct dilatation. Multiple filling defects (arrowheads) 
noted within dilated bile ducts suggest presence of Clonorchis sinensis worms. CT = computed tomography, MR = magnetic resonance
A B
Fig. 6. Recurrent pyogenic cholangitis in 63-year-old male.
A. Nonenhanced CT image shows radiopaque stones (arrows) in dilated bile ducts in right posterior segment of liver. B. Contrast-enhanced CT 
image shows dilated central bile ducts (arrows) and rounded liver appearance with marked hypertrophy of caudate lobe (arrowhead). C. MR 
cholangiography image demonstrates bile duct stones as multiple filling defects (arrows) with bile duct stricture (arrowhead). CT = computed 
tomography, MR = magnetic resonance
A B C
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is more easily diagnosed with CT. In cases of Clonorchis 
sinensis infestation, cholangiography shows diffuse uniform 
dilatation of the peripheral intrahepatic bile ducts without 
a focal obstructive lesion. Flukes are occasionally visualized 
in the dilated bile ducts as filling defects (Fig. 7) (45).
The complications of RPC include biloma, hepatic abscess, 
inflammatory pseudotumor, thrombophlebitis of portal 
or hepatic veins, and cholangiocarcinoma (38). Hepatic 
abscesses can develop in up to 20% of these patients (43). 
The most threatening complication is cholangiocarcinoma, 
which is detected in 2 to 6% of patients with RPC (46). 
Cholangiocarcinoma most commonly occurs in atrophic 
hepatic segments or segments harboring many stones (Fig. 
8) (35). Recurrent bacterial infection, bile stasis, and 
chronic irritation by stones are suggested as carcinogenic 
factors (47). Accurate diagnosis of cholangiocarcinoma 
in patients with RPC can be more difficult than in the 
general population, because biliary and parenchymal 
changes in underlying RPC can hinder the early detection of 
cholangiocarcinoma. 
Recurrent pyogenic cholangitis sometimes mimics the 
imaging findings of PSC, which can also be accompanied by 
multifocal biliary strictures and hepatolithiasis. However, 
the involvement of both intrahepatic and extrahepatic 
bile ducts, a beaded appearance, and biliary diverticulum 
suggest PSC rather than RPC (Table 1) (38). Intraductal 
papillary neoplasm of the bile ducts can sometimes 
resemble RPC, as both present as nodular lesions in a 
Fig. 8. Cholangiocarcinoma arising from recurrent pyogenic cholangitis in 82-year-old female.
A. Dilated left IHD (arrowheads) containing IHD stones is noted on contrast-enhanced CT image. B. Patient underwent follow-up CT scan after 4 
years. Axial contrast-enhanced CT scan shows newly developed, soft-tissue lesion (arrow) in left lobe of liver causing bile duct dilatation, as well as 
narrowing of left portal vein. Lesion was confirmed as cholangiocarcinoma after surgery. CT = computed tomography, IHD = intrahepatic bile duct
A B
Fig. 9. Ischemic cholangitis after transcatheter arterial chemoembolization for hepatocellular carcinoma in 74-year-old male.
A. Nonenhanced T1-weighted axial MR image detects multiple, hyperintense biliary casts in right intrahepatic bile duct (arrows). B. T2-weighted 
axial MR image depicts multiple bilomas (arrowheads). MR = magnetic resonance
A B
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dilated bile duct. The presence of contrast enhancement is 
suggestive of intraductal papillary neoplasm (38).
The treatment goals in RPC are complete removal of 
bile duct stone and bile stasis for the prevention of 
acute episodes of cholangitis and further stone formation 
(48). Therapeutic options include antibiotics for acute 
cholangitis, endoscopic procedures such as stricture 
dilatation or stone removal, biliary drainage, and surgical 
procedures such as biliary bypass, segmental hepatic 
resection or liver transplantation (40). A multidisciplinary 
approach is useful for proper management in patients with 
RPC. When a malignancy is suspected, biopsy or fine needle 
aspiration should be considered.
Ischemic Cholangitis
Ischemic cholangitis is defined as ischemia-induced 
bile duct injuries due to various causes. The bile ducts are 
vulnerable to ischemic injuries as the blood supply to the 
bile ducts depends completely on the arterial supply in 
contrast to the hepatic parenchyma, which has a dual blood 
supply from the hepatic artery and the portal vein (49). 
Among the various conditions that compromise the arterial 
supply and can cause ischemic cholangitis, iatrogenic 
causes including liver transplantation, hepatic arterial 
infusion of chemotherapeutic agents, and vessel injury 
during biliary or pancreatic surgery constitute the most 
common etiology (1, 50, 51). Ischemic cholangitis can exist 
in patients with hereditary hemorrhagic telangiectasia or 
polyarteritis nodosa (1, 51).
Pathological features of ischemic cholangitis vary 
depending on the degree and extent of hepatic arterial 
insufficiency and the stages of ischemic cholangitis (51). 
In the acute stage of ischemic cholangitis, desquamated 
ischemic biliary epithelium with other bile components 
forms biliary casts. Dilatation of the bile ducts is commonly 
seen at this stage, probably due to obstruction by the casts 
and a reaction to ischemic injury (51). When ischemic insult 
is more severe, necrosis involving the full thickness of the 
bile ducts occurs and spilled bile in the hepatic parenchyma 
creates biloma (51). As the disease progresses, focal or 
diffuse fibrous strictures may develop at a later stage of 
ischemic cholangitis (51). 
Diagnosis can be made according to the imaging 
features compatible with ischemic injury and evidence of a 
compromised arterial supply (51). The clinical and imaging 
features are closely related to the stage of the ischemic 
cholangitis. At the acute stage of ischemic cholangitis, 
the patients usually present with fever, abdominal pain, 
jaundice, and biliary sepsis. At this stage, the radiologic 
findings of biliary casts include intraductal filling defects 
in the dilated bile duct showing high signal intensity on 
nonenhanced T1-weighed MR images (Fig. 9) (52). At the 
acute stage of ischemic cholangitis, biliary casts appear 
similar to intraductal stones. However, they usually differ 
in their shapes, as biliary casts appear linear or have a 
branching pattern, whereas stones are usually oval or round 
(52). In severe ischemic injury, bile duct necrosis presents 
as tubular low density or intensity structures along the 
portal tracts on enhanced CT or MR images (Fig. 10) (51). 
Cholangiography in ischemic cholangitis shows dilated bile 
ducts with irregular margins and intraluminal filling defects 
(51). Bilomas can appear as an intrahepatic fluid collection 
usually located in the vicinity of the injured bile ducts (Figs. 
9, 10) (53). At the chronic stage of ischemic cholangitis, 
the clinical symptoms and laboratory profile include 
progressive or fluctuating cholestasis. As the disease 
Fig. 10. Ischemic cholangitis after hepatic arterial embolization for postoperative pseudoaneurysm in 50-year-old female.
A. At acute stage, contrast-enhanced axial CT image shows bile duct necrosis (arrows) and biloma (arrowhead). B, C. Contrast-enhanced axial CT 
scan (B) and percutaneous cholangiography (C) obtained 3 months following embolization, demonstrate multifocal bile duct stricture (arrows) 
and dilatation (arrowheads) that are typical features of chronic ischemic cholangitis. CT = computed tomography
A B C
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progresses, focal or diffuse strictures may develop at a later 
stage. Cholangiographic findings of ischemic cholangitis 
at this stage include multifocal biliary strictures and 
dilatation, both of which can mimic the findings of PSC (Fig. 
10) (51). The clinical context and predominant location of 
ischemic strictures, i.e., the middle third of the CBD and the 
hilar bile duct, are suggestive of ischemic cholangitis rather 
than PSC (51). 
Appropriate treatment option in ischemic cholangitis 
should be based on the individual patient’s clinical setting. 
In the transplanted patients with large artery occlusion, 
restoration of arterial flow can be attempted using 
thrombolytic agents, balloon angioplasty or stenting and 
surgical revision. On the other hand, in patients with small 
artery ischemic injuries, management of complications 
caused by bile duct injury may be more important as there 
is no specific curative method. Endoscopic procedures 
allow removal of biliary casts, and percutaneous drainage 
is useful for biloma drainage and decompressing dilated 
bile ducts in ischemic cholangitis. Biliary bypass surgery 
can be performed for bile duct reconstruction in ischemic 
cholangitis (51).
AIDS-Related Cholangitis
Acquired immunodeficiency syndrome-related cholangitis 
is a form of secondary sclerosing cholangitis occurring 
in patients with human immunodeficiency virus (HIV) 
infection. AIDS-related cholangitis typically affects 
advanced HIV-infected patients with markedly decreased 
immune function (CD4 count < 100/mm3) (54, 55). The 
suggested mechanisms of AIDS-related cholangitis include 
randomly occurring infections involving the bile ducts, 
ischemia, autonomic nerve injury, and direct invasion 
of bile duct epithelium by the HIV itself (56, 57). The 
most common pathogens in AIDS-related cholangitis are 
cytomegalovirus, Cryptosporidium parvum, Mycobacterium 
avium complex, and herpes simplex virus, although no 
definite pathogen is identified in almost 50% of these 
patients (34). The typical clinical manifestations in AIDS-
related cholangitis include right upper abdominal pain, as 
well as elevated alkaline phosphatase and transaminase 
levels. Associated papillary stenosis may result in more 
intense abdominal pain (58). 
On CT and MR imaging, enhanced wall thickening of the 
extrahepatic bile duct and the intrahepatic bile ducts can 
be seen in AIDS-related cholangitis (Fig. 11) (59, 60). 
Cholangiographic findings in AIDS-related cholangitis 
include multifocal strictures and dilatation of intrahepatic 
and extrahepatic bile ducts resembling those seen in 
patients with PSC (Fig. 11) (34, 59). In AIDS-related 
cholangitis, endoscopic cholangiography features of 
papillary stricture include tapered narrowing in the terminal 
portion of dilated CBD and marked and delayed contrast 
retention (Fig. 11) (59, 61). The patient’s clinical history, as 
well as some imaging features including papillary stenosis 
and a long extrahepatic bile duct stricture, can also help to 
differentiate AIDS-related cholangitis from PSC (58, 59). 
Although antimicrobial therapy could be used for 
opportunistic infections in AIDS-related cholangitis, it is 
reported to be mostly ineffective (62). Sphincterotomy is 
the primary therapy for patients with papillary stenosis (58). 
For biliary stricture in AIDS-related cholangitis, endoscopic 
balloon dilatation and stent placement may be performed (63).
Fig. 11. AIDS-related cholangitis with cytomegalovirus (CMV) infection in 43-year-old male.
A, B. Contrast-enhanced axial CT images show multifocal stricture and wall thickening in intrahepatic bile ducts (arrows). Papillary stenosis 
with enhancement (arrowhead) is also seen. C. On endoscopic cholangiography, diffuse stricture is noted in intrahepatic bile ducts (arrow). 
Common duct also shows dilatation and subtle mucosal irregularity (arrowhead). Endoscopic biopsy confirmed CMV infection. AIDS = acquired 
immunodeficiency syndrome, CT = computed tomography
A B C
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Eosinophilic Cholangitis
Eosinophilic cholangitis is defined as eosinophilic 
infiltration of the biliary system. Although there have been 
anecdotal case series in the English literature (64-66), 
patients with eosinophilic cholangitis generally present 
with jaundice, which is often associated with eosinophilic 
gastroenteritis (64). Peripheral eosinophilia is the most 
helpful laboratory finding, even though it is reported in 
Fig. 12. Eosionophilic cholangitis in 43-year-old male with hypereosinophilia.
A. Contrast-enhanced axial CT image demonstrates ill-defined soft-tissue lesions along periportal space (arrows). B. MR cholangiography 
shows focal smooth narrowing in left hepatic duct (arrows). Lesion was confirmed as eosinophilic infiltration after liver biopsy. CT = computed 
tomography, MR = magnetic resonance
A B
Fig. 13. Summary of imaging features of sclerosing cholangitis. Red lines along bile ducts indicate sites of frequent involvement 
according to etiologies of sclerosing cholangitis. Primary sclerosing cholangitis (PSC). Both intra- and extrahepatic bile ducts are usually 
involved in PSC. Beaded and pruned appearance of bile ducts, and diverticulum-like outpouching are characteristic imaging features of PSC. 
Immunoglobulin G4-related sclerosing cholangitis (IgG4-SC). Most commonly involved location is intrapancreatic bile duct followed by hilar 
bile ducts. Circumferential and delayed enhanced wall thickening with visible lumen is suggestive of IgG4-related SC. Findings of autoimmune 
pancreatitis can frequently be accompanied with IgG4-related SC. Recurrent pyogenic cholangitis (RPC). Most frequently involved segments are 
left lateral segment and right posterior segment of liver. RPC is characterized by intrahepatic bile duct stones, central bile duct dilatation, and 
decreased arborization of peripheral ducts. Ischemic cholangitis. Most vulnerable location is middle third of common bile duct. At acute stage, 
biliary casts and bilomas are common. As disease progresses to chronic stage, focal or diffuse bile duct stricture may develop. AIDS-related 
cholangitis. Long segmental stricture of extrahepatic bile duct and papillary stenosis are key imaging findings. Eosinophilic cholangitis. Wall 
thickening in proximal common bile duct and cystic duct is commonly seen. AIDS = acquired immunodeficiency syndrome
Primary sclerosing cholangitis
Ischemic cholangitis
IgG4-related sclerosing cholangitis
AIDS-related cholangitis
Recurrent pyogenic cholangitis
Eosinophilic cholangitis
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only approximately half of the patients with eosinophilic 
cholangitis (64). Histopathologically, eosinophilic 
cholangitis is characterized by dense transmural eosinophilic 
infiltration associated with other inflammatory cell 
infiltration in the bile ducts (65). A thickened fibromuscular 
layer and slight fibrosis in the subserosal layer are also 
present with eosinophilic cholangitis (65).
Imaging findings in eosinophilic cholangitis mentioned in 
previous reports include: wall thickening of the CBD, cystic 
duct, and gallbladder; diffuse bile duct stricture from the 
hepatic hilum to the intrahepatic duct; focal stricture of the 
common hepatic duct at the cystic duct insertion level; and 
mild smooth narrowing of the proximal common duct (Fig. 
12) (1, 16, 64, 65, 67). Although a preoperative diagnosis 
of eosinophilic cholangitis is challenging due to its 
nonspecific imaging features, it should be considered when 
bile duct wall thickening is present with involvement of the 
cystic duct, the gallbladder, and peripheral eosinophilia. 
Patients with eosinophilic cholangitis show a favorable 
response to corticosteroids and often show a self-limited 
disease course without treatment (16, 66, 68, 69).
Systemic Approach for Sclerosing Cholangitis
Before arriving at the differential diagnosis of sclerosing 
cholangitis, it is critical to exclude malignant bile duct 
strictures, especially when a single segmental bile duct 
wall thickening and/or stricture is detected. The following 
image features favor malignant biliary strictures rather 
than sclerosing cholangitis: a narrowed segment with 
Fig. 14. Systemic approach of sclerosing cholangitis. This diagram shows approach to differential diagnosis of sclerosing cholangitis based 
on clinical setting, laboratory findings, as well as typical imaging features. AIDS = acquired immunodeficiency syndrome, EHD = extrahepatic bile 
duct, Hx = history, IBD = inflammatory bowel disease, IgG4-SC = immunoglobulin G4-related sclerosing cholangitis, IHD = intrahepatic bile duct, 
PSC = primary sclerosing cholangitis, RPC = recurrent pyogenic cholangitis, TACE = transarterial chemoembolization
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hyperenhancement relative to the liver seen during the 
portal-venous phase; long length involved (> 12 mm); 
prominent bile duct thickening (> 3 mm); an indistinct 
outer margin; luminal irregularity; and asymmetry (70). 
After excluding malignant biliary strictures, the next step 
is to distinguish between PSC and secondary sclerosing 
cholangitis. Figure 13 summarizes the characteristic 
imaging features of sclerosing cholangitis according 
to the underlying etiologies. It is often challenging 
to differentiate the underlying etiologies of sclerosing 
cholangitis based solely on the morphological features. 
Therefore, the demographics, laboratory profiles, and 
patient’s past medical history should be considered together 
with the imaging features. A systematic approach (Fig. 14) 
combined with the appropriate clinical settings and imaging 
findings, can be helpful for differentiating the various 
causes of sclerosing cholangitis. Pathologic confirmation, 
such as biopsy, is necessary in patients with an inconclusive 
diagnosis. In cases suspected of IgG4-SC, steroid therapy 
can be attempted for diagnostic and therapeutic purposes 
in a selected patient group.
CONCLUSIONS
There is a wide spectrum of causes of sclerosing 
cholangitis, including PSC and secondary sclerosing 
cholangitis caused by various conditions including IgG4-
SC, RPC, ischemic cholangitis, AIDS-related cholangitis, 
and eosinophilic cholangitis. Several characteristic 
imaging features are suggestive of the underlying causes 
of sclerosing cholangitis, however, these imaging features 
substantially overlap. A systematic approach combined with 
appropriate clinical settings and imaging findings, may help 
to differentiate various causes of sclerosing cholangitis and 
ultimately to guide the appropriate patient management.
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